A Promising New Treatment Option for Low-Grade Gliomas
- Many low-grade gliomas have something known as an IDH mutation. These mutations can help promote tumor growth.
- A drug called vorasidenib is an exciting new targeted treatment option for low-grade gliomas that have an IDH-mutation.
- Vorasidenib has a favorable toxicity profile compared to other treatments like chemotherapy and radiation, so eligible patients can take the drug with less interference in their daily lives. Possible side effects include fatigue, digestive issues, decreased appetite, and stress to the liver.
- With each new INDIGO update, PFS has grown for patients with Grade 2 glioma treated with vorasidenib after surgery — 27.7 months in 2023, extended further in the 2025 Lancet Oncology update, and now 44.1 months in 2026.
- “Vorasidenib is an oral medication that patients take once a day. It’s something that they can easily do throughout the course of their treatment,” Dr. Ashley Ghiaseddin, a neurosurgeon at the University of Florida, tells SurvivorNet.
“Vorasidenib is an oral medication that patients take once a day. It’s something that they can easily do throughout the course of their treatment,” Dr. Ashley Ghiaseddin, a neurosurgeon at the University of Florida Health in Gainesville, Florida, tells SurvivorNet. “They don’t have to go to the hospital to do this. It can be done at their home.”
Read MoreVorasidenib, a novel IDH inhibitor, works by deactivating the mutated IDH1/2 enzymes, halting the production of D-2-hydroxyglutarate. This approach directly targets the vulnerabilities of the tumor cells — and offers a more precise treatment option that is less toxic to patients.
The Impact of the INDIGO Trial
The INDIGO Trial marked a pivotal moment in glioma research and treatment. Patients receiving Vorasidenib experienced a substantial extension in progression-free survival, highlighting the drug’s ability to manage tumor growth effectively over time. This is particularly important for patients with low-grade gliomas, as delaying the need for aggressive treatments such as chemotherapy or radiation can significantly improve quality of life.
In the trial, Vorasidenib not only demonstrated its efficacy in controlling tumor progression but also showcased its potential to shift the treatment paradigm. By targeting the underlying genetic and metabolic drivers of glioma, this medication offers a more tailored and less invasive approach compared to traditional therapies. The findings underscore the importance of precision medicine in oncology and open the door for further research into IDH inhibitors and their applications.
What are the Side Effects?
While Vorasidenib is generally well-tolerated, like any medication, it comes with potential side effects. These side effects are typically mild to moderate in severity and manageable with appropriate care.
The most common side effects reported include:
- Fatigue: Many patients experience a sense of tiredness or reduced energy levels.
- Nausea and Diarrhea: Digestive discomfort is relatively common but usually temporary.
- Decreased Appetite: A reduced desire to eat may occur during treatment.
- Liver Toxicity: Elevated liver enzymes have been observed in some patients, indicating potential liver stress. Regular monitoring of liver function tests is essential to ensure safety during treatment.
- Neurological Effects: Dizziness or confusion are less common but may occur in some individuals. Patients experiencing these effects should report them to their healthcare provider promptly.
Overall, the safety profile of Vorasidenib makes it a viable option for many patients, particularly given its potential to delay the need for more intensive treatments.
“This has really been a treatment that has been very well-tolerated with very early success that’s been reassuring to the community that this is something we can offer patients even when they may not have other great options,” Dr. Ghiaseddin explains.
Delaying the Need for Chemotherapy or Radiation
One of the most promising aspects of Vorasidenib is its ability to delay the need for chemotherapy or radiation, which have long been standard treatments for low-grade gliomas. These traditional therapies, while effective, often come with significant side effects, including cognitive impairment, fatigue, and other long-term complications. Delaying their use can significantly enhance a patient’s quality of life.
Dr. Ghiaseddin emphasizes the importance of discussing all treatment options with a healthcare provider.
“This is a perfect way to use this medication and try to give patients longer time before needing more substantial treatments such as chemotherapy and/or radiation,” he explains. By using Vorasidenib as an early intervention, patients can enjoy extended periods of stability and avoid the harsher side effects associated with more aggressive treatments.
What’s Next?
The development of IDH inhibitors like Vorasidenib represents a significant advancement in the field of oncology. By targeting the specific genetic mutations that drive tumor growth, these drugs offer a more personalized approach to cancer treatment. This shift toward precision medicine aligns with broader trends in healthcare, where treatments are increasingly tailored to the unique characteristics of each patient’s disease.
Beyond low-grade gliomas, IDH inhibitors have potential applications in other cancers that harbor IDH mutations. Ongoing research aims to explore these possibilities, potentially expanding the reach of these groundbreaking therapies to benefit even more patients.
The Patient Experience
For patients, the introduction of Vorasidenib offers hope and a sense of control in the face of a challenging diagnosis. By delaying the need for chemotherapy and radiation, this treatment allows patients to maintain their quality of life for longer periods. Additionally, the relatively mild side effect profile of the drug makes it a more tolerable option compared to traditional therapies.
Patients and their families are encouraged to have open and honest discussions with their healthcare teams about the potential benefits and risks of IDH inhibitors. Understanding the treatment plan, monitoring progress, and addressing any concerns are key components of successful care. The introduction of Vorasidenib highlights the importance of staying informed about new advancements and participating in clinical trials when appropriate.
Questions to Ask Your Doctor
If you have been diagnosed with glioma and are beginning the treatment process, consider asking your doctor the following questions.
- Has my glioma been tested for mutations?
- Am I eligible for an IDH-inhibitor like vorasidenib?
- What would the treatment path look like with vorasidenib?
- How will I be monitored throughout the treatment process?
Learn more about SurvivorNet's rigorous medical review process.
